Orphenadrine XR Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Orphenadrine citrate extended-release (ER) tablets are occasionally contacting their prescribers after being unable to fill their prescriptions at local pharmacies. While there is no declared national shortage of the oral formulation as of 2026, providers should be aware of the factors contributing to localized availability gaps and have a plan for managing affected patients.

Current Availability Status (2026)

As of early 2026, oral Orphenadrine citrate 100 mg extended-release tablets are NOT on the FDA Drug Shortage Database or the ASHP Drug Shortages list. Multiple generic manufacturers are actively producing this formulation, including Amneal Pharmaceuticals of New York, American Health Packaging, Impax Laboratories, and A-S Medication Solutions.

The 2023 shortage involved only the injectable formulation (30 mg/mL, 2 mL vials), triggered by the February 2023 closure of Akorn Pharmaceuticals, which had held approximately 75% market share for that product. Hikma Pharmaceuticals' injectable vials became available as of August 2023, largely resolving that shortage. Oral tablets were not affected by the Akorn closure.

Why Patients Are Reporting Difficulty Finding Orphenadrine XR

Several structural factors contribute to localized stock-outs for orphenadrine ER tablets even in the absence of an official shortage:

Low prescription volume: Orphenadrine ER is a less frequently prescribed muscle relaxant compared to cyclobenzaprine or methocarbamol. Pharmacies optimize inventory based on demand, resulting in thin stocking levels.

Generic manufacturer fragmentation: Different pharmacies source from different generic manufacturers. Temporary production issues at one manufacturer can affect specific pharmacy chains or regions while others remain unaffected.

Brand discontinuation confusion: The brand Norflex has been discontinued. Patients and occasionally pharmacy staff may confuse this with the generic being discontinued, creating unnecessary barriers to dispensing.

Regional distributor variability: Wholesaler-level supply fluctuations can create regional pockets of scarcity that resolve within days.

Clinical Profile of Orphenadrine ER: Key Prescribing Considerations

Before transitioning a patient to an alternative, it's worth reviewing what makes orphenadrine ER a distinct option within the muscle relaxant class:

Twice-daily dosing: The extended-release formulation allows for a convenient BID schedule (100 mg q12h), improving adherence compared to TID or QID alternatives.

Not a controlled substance: Orphenadrine ER is not DEA-scheduled, simplifying prescribing. However, it has been noted to have chronic abuse potential for euphoric effects and should still be monitored for misuse.

Anticholinergic burden: Orphenadrine's anticholinergic properties (approximately 58% as potent as atropine) mean it is generally not appropriate for older adults. It is included on the Beers Criteria list of medications generally avoided in patients ≥65 years.

Multiple mechanisms: Orphenadrine acts as an mACh receptor antagonist, NMDA receptor antagonist, and norepinephrine-dopamine reuptake inhibitor — which may contribute to both efficacy and its analgesic properties beyond simple CNS sedation.

Contraindications: Glaucoma, prostatic hypertrophy/bladder neck obstruction, myasthenia gravis, megaesophagus, peptic ulcers, and pyloric or duodenal obstruction.

Alternative Therapeutic Options for Providers to Consider

If a patient cannot obtain orphenadrine ER, the following are evidence-supported alternatives for acute musculoskeletal conditions:

Cyclobenzaprine (5–10 mg TID, or 15–30 mg ER QD): Highest evidence base in the class; tricyclic-like structure warrants caution in cardiac disease; avoid in patients receiving MAOIs or with recent MI.

Methocarbamol (750–1500 mg QID): Less sedating, no anticholinergic effects, well-tolerated, low cost. Can cause brown/green urine discoloration (benign).

Tizanidine (2–4 mg TID PRN): Alpha-2 agonist; good evidence base; monitor for hypotension; contraindicated with fluvoxamine and ciprofloxacin due to CYP1A2 interactions; hepatotoxicity risk with chronic use.

Metaxalone (800 mg TID–QID): Least sedating option; contraindicated with liver or kidney impairment; generally well-tolerated in working-age adults.

How to Help Patients Locate Orphenadrine XR

If your patient can't locate Orphenadrine XR and you don't want to change therapy, consider recommending medfinder for providers. medfinder calls pharmacies near the patient's location to identify which ones can fill the prescription, and texts the results directly to the patient — reducing the burden on your office staff and helping patients avoid unnecessary medication gaps.

Documentation and Continuity of Care Notes

If you prescribe a bridge medication while your patient locates Orphenadrine XR, document the clinical rationale and note that the switch is intended to be temporary. If converting to a different agent permanently, update the problem list and ensure any new drug-drug interaction checks are run — particularly for CNS depressants, opioids, and anticholinergics in the case of the alternatives listed above.